How bankrupt Pa. drug firm Endo could earn $265 million on an ‘exceptionally powerful opioid’ it removed twice from market

  • 📰 PhillyDailyNews
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 67%

Nederland Nieuws Nieuws

Nederland Laatste Nieuws,Nederland Headlines

Daily News | How bankrupt Pa. drug firm Endo could earn $265 million on an ‘exceptionally powerful opioid’ it removed twice from market

in September. Pennsylvania Attorney General Josh Shapiro was one of the seven whose filing called the top executive pre-bankruptcy bonuses “excessive.”

In 1970, 309 “addict-patients” at the city-run Philadelphia General Hospital spoke about their drug abuse. One-in-five said they abused Numorphan at least once, according to the 1972 published report on the findings. In 1982, Endo’s then-owner DuPont withdrew Numorphan tablets from the market for “commercial reasons” and amid “anecdotal reports of abuse by injection,” according to a FDA review of oxymorphone’s regulatory history.

Wij hebben dit nieuws samengevat zodat u het snel kunt lezen. Bent u geïnteresseerd in het nieuws, dan kunt u hier de volledige tekst lezen. Lees verder:

 /  🏆 89. in NL
 

Bedankt voor uw reactie. Uw reactie wordt na beoordeling gepubliceerd.

Nederland Laatste Nieuws, Nederland Headlines